| Methods |
2‐week washout; 4‐week single‐blind placebo run‐in; inclusion criteria= mean supine DBP 95‐114 mm Hg during last 2 weeks of run‐in, which could not vary by > 7mm Hg from visit to visit or by > 10mm Hg over this 2‐week period, and mean supine SBP 140‐200 mm Hg at randomization; 8‐week double‐blind treatment |
| Participants |
Telmisartan 20‐160 mg: n=209(117 males,92 females); mean age=51 years; ITT(n=208) baseline supine SBP=153.2(12.0) mm Hg, DBP=100.7(4.6) mm Hg, HR=71.2(9.2) bpm;
Placebo: n=74(45 males,29 females); mean age=55 years; ITT(n=73) baseline supine SBP=153.7(11.3) mm Hg, DBP=100.3(3.9) mm Hg, HR=71.9(9.3) bpm |
| Interventions |
Telmisartan 20 mg once daily;
Telmisartan 40 mg once daily;
Telmisartan 80 mg once daily;
Telmisartan 160 mg once daily;
Placebo;
taken at 8AM and 1h before breakfast |
| Outcomes |
Mean change from baseline in trough supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SE of change reported, endpoint BP and SD not reported, baseline SD reported; calculated SD from N and SE; BP data from Table IV, p. 841 and Figure 2, p. 843; Jadad score=5; funding source= Boehringer Ingelheim |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
